Zoetis Inc. reported fourth‑quarter and full‑year 2025 results that beat consensus estimates. Revenue rose 3% to $2.39 billion in the quarter and 2% to $9.47 billion for the year, while adjusted net income climbed 3% to $648 million and $2.80 billion, respectively. Diluted earnings per share were $1.48 in Q4 and $6.41 for the year, surpassing analyst expectations of $1.40 and $6.30 by $0.08 and $0.11, a beat of 5.7% and 1.8%.
The revenue increase was driven by a 9% acceleration in the livestock segment and a 12% operational growth in the Simparica franchise, offsetting a 11% decline in the osteoarthritis pain franchise and only 1% growth in dermatology. International sales grew 2.5%–3.5% in Q4, a trend the company said it does not expect to recur in fiscal 2026. Compared with Q4 2024, revenue was $2.30 billion and adjusted net income was $632 million, indicating a modest year‑over‑year lift in both metrics. For the full year, 2024 revenue was $9.30 billion and adjusted net income $2.70 billion, so the 2025 results represent a 2% revenue gain and a 6% income gain.
Operating margin in Q4 2025 was 31.9%, down from 32.9% a year earlier, reflecting a slight compression in the U.S. segment amid competitive pricing pressures. Net margin stood at 28.2%, consistent with the company’s focus on maintaining profitability while investing in growth initiatives. The margin profile, combined with the international sales uptick, explains why the company was able to beat EPS expectations despite the headwinds in key companion‑animal franchises.
Management highlighted the resilience of the portfolio. CEO Kristin Peck said, "Zoetis delivered solid results in 2025, demonstrating the strength and resilience of our portfolio across species, geographies, and channels. Leadership across key brands and categories drove continued growth, even as we navigated a dynamic operating environment." CFO Wetteny Joseph added, "We expect Companion Animal business to remain a key growth driver in 2026, supported by a differentiated portfolio even as competition in parasiticide and canine dermatology intensifies—dynamics that are reflected in the guidance range." The company guided 2026 revenue to $9.83 billion–$10.03 billion, adjusted net income to $2.98 billion–$3.03 billion, and diluted EPS to $7.00–$7.10, signaling confidence in continued growth while acknowledging competitive pressures.
Market reaction was muted, with the stock falling 1.96% in pre‑market trading and a 6% decline the previous session. Investors focused on the slowing growth in the osteoarthritis pain franchise and modest dermatology performance, viewing these as potential long‑term headwinds despite the earnings beat. The negative reaction underscores that investors weigh future growth prospects more heavily than short‑term earnings surprises.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.